Benjamin Levy, MD, has been named clinical director of medical oncology and medical director of thoracic oncology for the Johns Hopkins Kimmel Cancer Center at Sibley Memorial Hospital.
Benjamin Levy, MD
Benjamin Levy, MD
Benjamin Levy, MD, has been named clinical director of medical oncology and medical director of thoracic oncology for the Johns Hopkins Kimmel Cancer Center at Sibley Memorial Hospital in Washington, DC.
Levy, former director of thoracic medical oncology and assistant professor of medicine at Mount Sinai’s Icahn School of Medicine, is developing one of the few multispecialty programs for lung cancer in the Washington, DC, region, integrating oncology, surgery, pathology and radiation oncology, and offering the latest clinical trials available at Johns Hopkins evaluating novel immunotherapeutic strategies, according to a release from Johns Hopkins. He will also direct clinical inpatient and outpatient operations of Sibley’s medical oncology services and oversee quality and safety standards across all Johns Hopkins Kimmel Cancer Center facilities.
Levy earned his medical degree at the Medical College of Georgia, completed a residency at Georgetown University, and completed his fellowship in hematology-oncology at Weill Cornell Medical College.
The Johns Hopkins Kimmel Cancer Center recently opened a 30,000-square-foot, state-of-the-art facility at Sibley, doubling its capacity for delivering cancer treatments. The Johns Hopkins Kimmel Cancer Center also has facilities at The Johns Hopkins Hospital; Johns Hopkins Bayview Medical Center in Baltimore; Suburban Hospital in Bethesda, Maryland; and the Johns Hopkins Health Care and Surgery Center at Green Spring Station in Lutherville, Maryland. Across all of its facilities, Johns Hopkins Kimmel Cancer Center specialists see more than 11,000 new patients each year.
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
April 23rd 2024During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
Read More
Biomarker Testing Paves the Way for Better Targeted Therapies in NSCLC
April 16th 2024At a live virtual event, Edward S. Kim, MD, MBA, discussed the evolving landscape of biomarker testing before making treatment decisions for patients with early-stage non–small cell lung cancer (NSCLC).
Read More